Format

Send to

Choose Destination
Int J Psychiatry Clin Pract. 2016 Nov;20(4):249-53. doi: 10.1080/13651501.2016.1213854. Epub 2016 Aug 23.

Potential drug-drug interaction in Mexican patients with schizophrenia.

Author information

1
a División Académica de Ciencias de la Salud , Universidad Juárez Autónoma de Tabasco , Villahermosa , Tabasco , México ;
2
b Instituto Nacional de Medicina Genómica (INMEGEN), Servicios de Atención Psiquiátrica (SAP), Secretaría de Salud , México , D. F , México ;
3
c Hospital General de Yajalón, Secretaría de Salud , Yajalón , Chiapas , México.

Abstract

OBJECTIVE:

The aim of this study was to observe potential drug-drug interactions in the medication of Mexican schizophrenic patients.

METHODS:

We performed a retrospective and cross-sectional study that was carried out in a psychiatric clinic. Only the prescriptions of patients with schizophrenia whose diagnoses were based on the DSM-IV instrument were included in this study. The Drug Interactions Checker software ( http://www.drugs.com/drug_interactions.html ) was used in this study to analyse potential drug-drug interactions.

RESULTS:

In total, 86 of 126 patients were at risk of potential drug-drug interactions. Haloperidol and biperiden was the most common drug pair of 232 pairs evaluated. In our study, 13.8% of drug-drug interaction showed a major level of severity, whereas in 83.2%, the interaction was moderate. Finally, central nervous system (CNS) depression and anticholinergic effect were the main possible effects of drug-drug interaction.

CONCLUSIONS:

Our results revealed a high number of patients with schizophrenia receiving two or more drugs. The potential drug-drug interactions observed in the Mexican population are consistent with the concomitant use of antipsychotics, benzodiazepines, and antidepressants prescribed in schizophrenia that could cause central nervous system (CNS) depression and anticholinergic effect. Drug-drug interaction must be considered when the patient with schizophrenia is medicated.

KEYWORDS:

Drug–drug interaction; Mexican population; schizophrenia

PMID:
27552677
DOI:
10.1080/13651501.2016.1213854
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center